what are glp-1 agonists GLP-1 Agonists in Cardiovascular Diseases:
Description
It balances pace with tolerability
However, abrupt discontinuation of GLP-1R agonists in patients with metabolic disorders may lead to rapid weight regain and potential exacerbation of IIH symptoms, as reported in a case study [101]
Moreover, efficacy was similar in the entire cohort of antibody-positive and antibody-negative patients (HbA1c change: -0.9% and -1.0%, respectively, with exenatide twice-daily
21 Similarly, Wilding et al demonstrated that in overweight or obese participants receiving 2.4 mg semaglutide, both total and regional visceral fat mass decreased, whereas lean body mass increased
The resulting concordance between the emulated and actual SUSTAIN-6 and SURPASS-CVOT trial estimates strengthen confidence in the internal validity of our findings for the successfully assessed endpoints
As their use continues to expand, emergency physicians are increasingly encountering their downstream effects
